相关实验视频

Updated: Sep 19, 2025

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

单细胞膜涂层的药物纳米晶体用于加强类风湿性关节炎的向治疗

Rongying Shi¹, Jiali Fu², Min Li²

¹Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, PR China; Sichuan Good Doctor Panxi Pharmaeceutical Co.Ltd, Xichang, Sichuan 615000, PR China.

Journal of controlled release : official journal of the Controlled Release Society

|June 3, 2025

概括

研究人员开发了针对类风湿性关节炎 (RA) 的新型单细胞膜涂层药物纳米晶体 (mMc@DNCs). 这种有针对性的输送系统有效地减少了关节炎症和损伤,毒性最小,提供了一个有前途的新型RA疗法.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
免疫学免疫学免疫学

背景情况:

类风湿性关节炎 (RA) 是一种具有复杂病理学的慢性自身免疫性疾病.
目前的RA治疗有局限性,包括副作用和低于最佳的疗效.
开发有针对性和安全的RA疗法是一个重大未满足的需求.

研究的目的:

开发一种针对类风湿性关节炎 (RA) 的新型药物输送平台.
创建单细胞膜涂层的药物纳米晶体 (mMc@DNCs) 进行向的输送.
共同制造NLRP3炎症酶抑制剂和德克萨米他,用于协同治疗RA.

主要方法:

制造具有高药物加载效率 (~70%) 的mMc@DNC.
在辅助剂诱导的关节炎大鼠模型中对mMc@DNCs的评估.
关节炎症,骨质侵蚀,软骨损伤和细胞因子水平 (TNF-α,IL-1β) 的评估.

主要成果:

在静脉注射后,mMc@DNCs在炎症关节中选择性积累.
观察到关节胀,骨质侵蚀和软骨损伤的显著减少.
在关节腔中抑制了促炎性细胞因子TNF-α和IL-1β的表达.
该联合配方表现出最小的目标外毒性.

结论:

mMc@DNCs代表了针对RA的有希望的向药物输送策略.
这个平台为RA提供了一个潜在的更安全,更有效的治疗方法.
该研究为RA治疗中先进的向药物输送提供了基础.

关键词:

德克萨米他是一种药物纳米晶体药物纳米晶体在MCC95050中,我们可以使用MCC950 一个单细胞单细胞.一个单细胞细胞膜.自然的目标是自然的目标.类风湿性关节炎类风湿性关节炎类风湿性关节炎

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...